I understand what you are trying to say JF, however you must put...

I understand what you are trying to say JF, however you must put things into perspective.
Take Rob and ENA as an example - mass intra-industrial campaign doing very well in a short period of time on the back of a very successful business model with infra-structure and an existing name with commercial products for sale. Completely different story.

Now Phosphagenics has a revolutionary platform delivery technology, with it's prime product line centring around the opioid patches, still in phase 1 stages.
We as investors know that the hard work has been done, that the patches are now primed and the trial process will now gather much momentum, however we are still not ready to exploit a product until at least multi-dose trials are done.
Imagine we started singing to the masses 18 months ago about our patch, only to come up against the major setbacks that took 12 months to overcome. We would have looked pretty silly IMO.
When the patch is tested at the next level, the green light will flash to finally tell the world we have arrived.
We know what TPM is capable of, but we need something solid and reliable to preach before we can dance with the stars, and this is reflecting in the price.
The Novartis license is the first external pharma light and more will start to appear over the next few months.
Yes pushing TPM PR is very important. Although I haven't done marketing, as a layman, I would suggest that it's all about the timing. It will come when it is ready. If not, don't worry I'll be one of the first to knock on the door at HQ.